好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Identification of a Unique Microglial Signature in Mice and Humans
MS and Related Diseases
IN9 - (-)
009
Microglia are resident myeloid-lineage cells in the CNS that function in the maintenance of normal tissue. To date there are no unique markers for microglia cells. The distinction between resident microglia and recruited mononuclear phagocytes is crucial, because it provides an approach to understand the biology of microglia and their relevance to disease.
We used three approaches to identify unique biological features of microglial cells: 1) generation of monoclonal antibodies against surface molecules on CNS derived adult microglia vs. peripheral monocytes; 2) gene and microRNA array analysis of these two populations and other immune cells; and 3) quantitative proteomic analysis between CNS derived adult microglia vs. peripheral Ly6C monocytes.
We have identified a microRNA/gene signature that is uniquely expressed in resident adult microglia in mice and humans. This molecular microglial signature was not observed in classically studied microglial cell lines or embryonic preparations of microglia, nor in peripheral immune cells or recruited mononuclear cells in animal models of MS, AD or ALS. Moreover, most of the identified unique microglial genes were downregulated during acute or chronic phases in EAE mice or during disease progression in ALS and AD. In freshly isolated post-mortem MS tissue, we identified activated microglia in association with plaques but not in unaffected brain regions. As part of this unique microglial signature, we identified unique surface markers related to TAM receptors. Targeting these receptors modulated microglia from an M1 to M2 phenotype both in vitro and in vivo.
Our findings redefine resident microglia as highly active in homeostasis and regulation of immune responses. They provide a new definition of resident microglia and utilize unique tools and methods which have not been available previously to address the biology of microglia in normal brain function and in neurologic disease.
Authors/Disclosures
Oleg Butovsky, PhD (Brigham and Women's Hospital/Harvard Medical)
PRESENTER 		No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
David Shprecher, DO, FAAN (Banner Sun Health Research Institute) Dr. Shprecher has received personal compensation for serving as an employee of Banner Health. Dr. Shprecher has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal. Dr. Shprecher has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanders+Parks. Dr. Shprecher has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. Dr. Shprecher has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Shprecher has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kyowa Kirin. Dr. Shprecher has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medplace. The institution of Dr. Shprecher has received research support from MJFF. The institution of Dr. Shprecher has received research support from Cognition Therapeutics. The institution of Dr. Shprecher has received research support from Biogen. The institution of Dr. Shprecher has received research support from Neuraly. The institution of Dr. Shprecher has received research support from Jazz Pharmaceuticals. The institution of Dr. Shprecher has received research support from Sanofi Aventis. The institution of Dr. Shprecher has received research support from Annovis. The institution of Dr. Shprecher has received research support from Neurocrine. The institution of Dr. Shprecher has received research support from Teva. The institution of Dr. Shprecher has received research support from Nuvelution. The institution of Dr. Shprecher has received research support from EIP Pharma. Dr. Shprecher has received personal compensation in the range of $500-$4,999 for serving as a Speaker with International Parkinson's and MDS. Dr. Shprecher has received personal compensation in the range of $5,000-$9,999 for serving as a Speaker with Parkinson's Movement Disorder Alliance.
Craig S. Moore, PhD (Memorial University of Newfoundland) Dr. Moore has nothing to disclose.
Jack P. Antel, MD, FAAN (Montreal Neurologic Hospital) Dr. Antel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for sanofi, roche, biogen, wave,nervgen. The institution of Dr. Antel has received research support from Novartis canada bristol myers squib. Dr. Antel has a non-compensated relationship as a past president with ACTRIMS that is relevant to AAN interests or activities.
Howard L. Weiner, MD (Brigham and Women'S Hospital) Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tiziana Life Sciences. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for vTv Therapeutics. Dr. Weiner has stock in vTv Therapeutics. The institution of Dr. Weiner has received research support from National Institute of Health. The institution of Dr. Weiner has received research support from National MS Society. The institution of Dr. Weiner has received research support from Genzyme Corp. The institution of Dr. Weiner has received research support from Genentech, Inc. . The institution of Dr. Weiner has received research support from Verily Life Sciences LLC. The institution of Dr. Weiner has received research support from EMD Serono, Inc..